Xymogen Athletix is designed for both competitive and recreational athletes, building on a 20-year legacy of trust, research and innovation and created with evidence-based ingredients, according to the company.
“Athletix was born from our family’s passion for performance and our responsibility to bring trusted, safe and science-backed nutrition to athletes everywhere,” said Brian Blackburn, Jr., chief science officer at Xymogen. “Every formula is NSF Certified for Sport and developed by health professionals who understand what it takes to fuel endurance, recovery and strength—without compromise.”
To be NSF Certified for Sport, a company must have a toxicological review of ingredients and verification that the formulas meet the claims and contents shown on their labels. The finished formulas must be tested for potentially harmful levels of contaminants, such as heavy metals, pesticides and more. And the formulas need to be screened for more than 290 athletic banned substances.
Xymogen is currently in discussion with professional athletes and trainers to integrate the new brand into their performance routines, highlighting its immediate relevance in the sports world, the company said. The product is recommended by pro leagues, including the MLB, NFL, NBA, NASCAR, PGA, USADA and others.
Xymogen Athletix is available online and through health professionals. Products cost between $55.99 to $94.99 and they include formulas like ATP Ignite Mixed Berry, ATP Ignite Workout Mixed Berry and XymoBolX Fruit Punch.
Beyond the Athletix brand, Xymogen also has several other products NSF Certified for Sport, including creatine and omega-3s.
About Xymogen
Headquartered in Orlando, Florida, Xymogen manufactures over 300 science-backed dietary supplements on its 309,000-square-foot campus. In 2024, the company had more than 430 employees and over $150 million in sales.
Xymogen is moving beyond its origins as a company that caters to approximately 30,000 physicians and their patients to one that markets and sells supplements to the population at large.
“We had to [expand] because we saw how the industry was changing, how people are taking health in their own hands,” Blackburn, Jr. told NutraIngredients earlier this year.
Part of its market appeal is that Xymogen’s supplement must be substantiated by human clinical studies, and the company will not rely on animal studies to prove efficacy.
When it comes to the supply chain, Xymogen will wait until an out-of-stock ingredient is back on the market to continue production rather than swap it out for a lesser quality one, Backburn, Jr. said.
